Breast cancer test gave Atossa a revenue boost in Q2

08/16/2013 | GenomeWeb Daily News (free registration)

Atossa Genetics posted $326,078 in revenue during the second quarter, up from $223,097 in the same period last year. The increase was fueled by sales of the company's ForeCYTE Breast Health Test, which stratifies patients' breast cancer risk based on mammary aspirate samples.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC